Glomerulonephritis following COVID-19 infection or vaccination: a multicenter study in South Korea

다국어 초록 (Multilingual Abstract)

Background: Despite the widespread impact of the severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019, COVID-19) and vaccination in South Korea, our understanding of kidney diseases following these events remains limited. We aimed to address this gap by investigating the characteristics of glomerular diseases following the COVID-19 infection and vaccination in South Korea. Methods: Data from multiple centers were used to identify de novo glomerulonephritis (GN) cases with suspected onset following COVID-19 infection or vaccination. Retrospective surveys were used to determine the COVID-19–related histories of patients who were initially not implicated. Bayesian structural time series and autoregressive integrated moving average models were used to determine causality. Results: Glomerular diseases occurred shortly after the infection or vaccination. The most prevalent postinfection GN was podocytopathy (42.9%), comprising primary focal segmental glomerulosclerosis and minimal change disease, whereas postvaccination GN mainly included immunoglobulin A nephropathy (IgAN; 57.9%) and Henoch-Schönlein purpura nephritis (HSP; 15.8%). No patient progressed to end-stage kidney disease. Among the patients who were initially not implicated, nine patients with IgAN/HSP were recently vaccinated against COVID-19. The proportion of glomerular diseases changed during the pandemic in South Korea, with an increase in acute interstitial nephritis and a decrease in pauci-immune crescentic GN. Conclusion: This study showed the characteristics of GNs following COVID-19 infection or vaccination in South Korea. Understanding these associations is crucial for developing effective patient management and vaccination strategies. Further investigation is required to fully comprehend COVID-19’s impact on GN.

참고문헌 (Reference)

• 1 Hasan Ali O, "Severe Coronavirus Disease 2019(COVID-19)is Associated With Elevated Serum Immunoglobulin(Ig)A and Antiphospholipid IgA Antibodies" 73 : e2869-, 2021
• 2 Park Jae Seok ; Lee Eunyoung, "Renal side effects of COVID-19 vaccines in patients with immunoglobulin A nephropathy" 41 : 124-127, 2022
• 3 Kronbichler A, "Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases" 36 : 1160-1168, 2021
• 4 Hilhorst M, "Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease : considerations from the Immunonephrology Working Group of the European Renal Association(ERA-IWG)" 38 : 1807-1816, 2023
• 5 Stevens KI, "Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS" 37 : 1400-1410, 2022
• 6 Lim JH, "New-onset kidney diseases after COVID-19 vaccination : a case series" 10 : 302-, 2022
• 7 Kim HJ, "New-onset class III lupus nephritis with multi-organ involvement after COVID-19 vaccination" 101 : 826-828, 2022
• 8 Ma Y, "New-onset IgA nephropathy following COVID-19 vaccination" 116 : 26-39, 2023
• 9 Bowe B, "Kidney outcomes in long COVID" 32 : 2851-2862, 2021
• 10 de Las Mercedes Noriega M, "Kidney biopsy findings in patients with SARS-CoV-2 infection or after COVID-19 vaccination" 18 : 613-625, 2023
• 11 Yeo SC, "Is immunoglobulin A nephropathy different in different ethnic populations?" 24 : 885-895, 2019
• 12 Brodersen KH, "Inferring causal impact using Bayesian structural time-series models" 9 : 247-274, 2015
• 13 Diebold M, "Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased" 102 : 1409-1419, 2022
• 14 Negrea L, "Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy" 99 : 1487-, 2021
• 15 Caza TN, "Glomerular disease in temporal association with SARS-CoV-2 vaccination : a series of 29 cases" 2 : 1770-1780, 2021
• 16 조아림 ; 이현순 ; Yoon Songuk ; Kim Eun Jung ; 서장원 ; 구자룡 ; Baek Seon Ha, "Focal segmental glomerulosclerosis following the Pfizer-BioNTech COVID-19 vaccine" 41 : 263-266, 2022
• 17 Uppal NN, "De Novo ANCA-associated vasculitis with glomerulonephritis in COVID-19" 5 : 2079-2083, 2020
• 18 Korea Disease Control and Prevention Agency (KDCA), "Coronavirus (COVID-19), Republic of Korea" KDCA
• 19 Lim CC, "COVID-19 vaccination in immunoglobulin A nephropathy" 78 : 617-, 2021
• 20 Li NL, "COVID-19 vaccination followed by activation of glomerular diseases : does association equal causation?" 100 : 959-965, 2021
• 21 Korea Disease Control and Prevention Agency (KDCA), "COVID-19 vaccination" KDCA
• 22 Brogan M, "COVID-19 and kidney disease" 74 : 1-13, 2023
• 23 Klomjit N, "COVID-19 and glomerular diseases" 8 : 1137-1150, 2023
• 24 Hyndman RJ, "Automatic time series forecasting : the forecast package for R" 27 : 1-22, 2008
• 25 Telenti A, "After the pandemic : perspectives on the future trajectory of COVID-19" 596 : 495-504, 2021
• 26 Ng JH, "Acute tubulointerstitial nephritis and COVID-19" 14 : 2151-2157, 2021
• 27 Hirsch JS, "Acute kidney injury in patients hospitalized with COVID-19" 98 : 209-218, 2020
• 28 Liew SK, "Acute interstitial nephritis following SARS-CoV-2 virus vaccination" 97 : 242-245, 2022
• 29 Tan FS, "Acute interstitial nephritis after COVID-19 vaccination" 15 : e246841-, 2022
• 30 Thammathiwat T, "ANCA associated glomerulonephritis following SARS-CoV-2 vaccination : a case series and systematic review" 11 : 983-, 2023
• 31 Canney M, "A population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination" 33 : 2247-2257, 2022
• 32 Kim Beop Chang ; Kim Han Seong ; Han Kum Hyun ; Han Sang Youb ; Jo Hyung Ah, "A case report of MPO-ANCA-associated vasculitis following heterologous mRNA1273 COVID-19 booster vaccination" 37 : e204-, 2022
• 33 Rahim SE, "A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination" 100 : 238-, 2021